Lupin launches generic Kapvay tablets in US
Mumbai: Pharma major Lupin announced the launch of its Clonidine Hydrochloride extended-release tablets for the treatment of attention deficit hyperactivity disorder (ADHD).
The Clonidine Hydrochloride extended-release tablets 0.1mg have received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin's Clonidine Hydrochloride ER tablets are the generic equivalent of Concordia International Corp's Kapvay® tablets. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.
Kapvay tablets had annual sales of approximately USD 66 million in the US.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd